Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

BACKGROUND: The optimal chemotherapy regimen for non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) remains unknown. Therefore, in this study, we investigated the real-world efficacy and safety of carboplatin (CBDCA) plus nab-paclitaxel (nab-PTX) as a first-line regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Igawa, Satoshi, Nishinarita, Noriko, Takakura, Akira, Ozawa, Takahiro, Harada, Shinya, Kusuhara, Seiichiro, Niwa, Hideyuki, Hosotani, Shinji, Sone, Hideyuki, Nakahara, Yoshiro, Fukui, Tomoya, Mitsufuji, Hisashi, Yokoba, Masanori, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298387/
https://www.ncbi.nlm.nih.gov/pubmed/30588105
http://dx.doi.org/10.2147/CMAR.S189556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298387/
https://www.ncbi.nlm.nih.gov/pubmed/30588105
http://dx.doi.org/10.2147/CMAR.S189556

Ejemplares similares